Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer

Authors: Marina Crespo-Bravo, Jeppe Thorlacius-Ussing, Neel I. Nissen, Rasmus S. Pedersen, Mogens K. Boisen, Maria Liljefors, Astrid Z. Johansen, Julia S. Johansen, Morten A. Karsdal, Nicholas Willumsen

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Collagens are the major components of the extracellular matrix (ECM) and are known to contribute to tumor progression and metastasis. There are 28 different types of collagens each with unique functions in maintaining tissue structure and function. Type XVII collagen (BP180) is a type II transmembrane protein that provides stable adhesion between epithelial cells and the underlying basement membrane. Aberrant expression and ectodomain shedding of type XVII collagen have been associated with epithelial damage, tumor invasiveness, and metastasis in multiple tumor types and may consequently be used as a potential (non-invasive) biomarker in cancer and treatment target.

Method

An ELISA targeting the type XVII collagen ectodomain (PRO-C17) was developed for use in serum. PRO-C17 was measured in a cohort of patients with 11 different cancer types (n = 214) and compared to healthy controls (n = 23) (cohort 1). Based on the findings from cohort 1, PRO-C17 and its association with survival was explored in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab in combination with chemotherapy (n = 212) (cohort 2).

Results

PRO-C17 was robust and specific towards the ectodomain of type XVII collagen. In cohort 1, PRO-C17 levels were elevated (p < 0.05) in serum from patients with CRC, kidney, ovarian, bladder, breast, and head and neck cancer compared to healthy controls. PRO-C17 was especially good at discriminating between CRC patients and healthy controls with an AUROC of 0.904. In cohort 2, patients with mCRC and high levels (tertile 3) of PRO-C17 had shorter overall survival (OS) with a median OS of 390 days compared to 539 days for patients with low levels of PRO-C17. When evaluated by multivariate Cox regression analysis, high PRO-C17 was predictive for poor OS independent of risk factors and the tumor fibrosis biomarker PRO-C3.

Conclusion

PRO-C17 measures the ectodomain of type XVII collagen in serum and is a promising non-invasive biomarker that can aid in understanding tumor heterogeneity as well as elaborate on the role of collagen XVII in tumor progression. Moreover, the findings in the study proposes PRO-C17 as novel biomarker of epithelial damage in specific cancer types including CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, de Boeck A, et al. The Extracellular Matrix regulates Cancer Progression and Therapy Response: implications for prognosis and treatment. Curr Pharm Des. 2009;15(12):1373–84.PubMed
3.
Karsdal M. Biochemistry of collagens: structure, function and biomarkers. 2nd ed. Academic Press; 2019.
4.
Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395–406.PubMedPubMedCentral
5.
Willumsen N, Jensen C, Green G, Nissen NI, Neely J, Nelson DM, et al. Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cell Mol Life Sci. 2022;79(4):204.PubMedPubMedCentral
6.
7.
8.
Izzi V, Heljasvaara R, Heikkinen A, Karppinen SM, Koivunen J, Pihlajaniemi T. Exploring the roles of MACIT and multiplexin collagens in stem cells and cancer. Semin Cancer Biol. 2020;62:134–48.PubMed
9.
Heljasvaara R, Aikio M, Ruotsalainen H, Pihlajaniemi T. Collagen XVIII in tissue homeostasis and dysregulation — Lessons learned from model organisms and human patients. Matrix Biol. 2017;57–58:55–75.PubMed
10.
Heikkinen A, Tu H, Pihlajaniemi T, Collagen XIII. A type II transmembrane protein with relevance to musculoskeletal tissues, microvessels and inflammation. Int J Biochem Cell Biol. 2012;44(5):714–7.PubMed
11.
12.
Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the Bullous Pemphigoid Autoantigen BP180. J Invest Dermatology. 1992;99(3):243–50.
13.
Snellman A, Tu H, Väisänen T, Kvist AP, Huhtala P, Pihlajaniemi T. A short sequence in the N-terminal region is required for the trimerization of type XIII collagen and is conserved in other collagenous transmembrane proteins. EMBO J. 2000;19(19):5051–9.PubMedPubMedCentral
14.
Hashimoto T. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 2002;21(7):1524–34.PubMedPubMedCentral
15.
Banyard J, Bao L, Zetter BR, Type XXIII. Collagen, a New Transmembrane Collagen identified in metastatic tumor cells. J Biol Chem. 2003;278(23):20989–94.PubMed
16.
Wakabayashi T. Transmembrane collagens in Neuromuscular Development and Disorders. Front Mol Neurosci. 2021;13.
17.
Nishie W, Lamer S, Schlosser A, Licarete E, Franzke CW, Hofmann SC, et al. Ectodomain Shedding generates neoepitopes on collagen XVII, the Major Autoantigen for Bullous Pemphigoid. J Immunol. 2010;185(8):4938–47.PubMed
18.
Schumann H, Baetge J, Tasanen K, Wojnarowska F, Schäcke H, Zillikens D, et al. The Shed Ectodomain of Collagen XVII/BP180 is targeted by Autoantibodies in different blistering skin Diseases. Am J Pathol. 2000;156(2):685–95.PubMedPubMedCentral
19.
Hofmann SC, Voith U, Schönau V, Sorokin L, Bruckner-Tuderman L, Franzke CW. Plasmin plays a role in the in vitro generation of the Linear IgA Dermatosis Antigen LADB97. J Invest Dermatology. 2009;129(7):1730–9.
20.
Yamauchi T, Matsushita S, Hashimoto T, Hirako Y. Major cleavage-dependent epitopes for linear IgA bullous dermatosis are formed at the boundary between the non-collagenous 16A and collagenous 15 domains of BP180. J Dermatol Sci. 2014;76(1):25–33.PubMed
21.
Toyonaga E, Nishie W, Izumi K, Natsuga K, Ujiie H, Iwata H, et al. C-Terminal Processing of Collagen XVII induces neoepitopes for Linear IgA Dermatosis Autoantibodies. J Invest Dermatology. 2017;137(12):2552–9.
22.
Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa Linear IgA Bullous Disease Antigen is identical to a portion of the Extracellular Domain of the 180 kDa Bullous Pemphigoid Antigen, BPAg2. J Invest Dermatology. 1998;110(3):207–10.
23.
Nie Z, Nagata Y, Joubeh S, Hashimoto T, Hirako Y, Owaribe K, et al. IgA antibodies of Linear IgA Bullous Dermatosis recognize the 15th Collagenous Domain of BP180. J Invest Dermatology. 2000;115(6):1164–6.
24.
Tasanen K, Tunggal L, Chometon G, Bruckner-Tuderman L, Aumailley M. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. Am J Pathol. 2004;164(6):2027–38.PubMedPubMedCentral
25.
Moilanen JM, Kokkonen N, Löffek S, Väyrynen JP, Syväniemi E, Hurskainen T, et al. Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer. Hum Pathol. 2015;46(3):434–42.PubMed
26.
Laval S, Laklai H, Fanjul M, Pucelle M, Laurell H, Billon-Galés A, et al. Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides. Oncogene. 2014;33(15):1934–44.PubMed
27.
Thangavelu PU, Krenács T, Dray E, Duijf PHG. In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clin Epigenetics. 2016;8(1):120.PubMedPubMedCentral
28.
Parikka M, Kainulainen T, Tasanen K, Väänänen A, Bruckner-Tuderman L, Salo T. Alterations of collagen XVII expression during Transformation of oral epithelium to Dysplasia and Carcinoma. J Histochem Cytochemistry. 2003;51(7):921–9.
29.
Jones VA, Patel PM, Gibson FT, Cordova A, Amber KT. The role of collagen XVII in Cancer: squamous cell Carcinoma and Beyond. Front Oncol. 2020;10.
30.
Galiger C, Löffek S, Stemmler MP, Kroeger JK, Mittapalli VR, Fauth L, et al. Targeting of cell surface proteolysis of collagen XVII impedes squamous cell carcinoma progression. Mol Ther. 2018;26(1):17–30.PubMed
31.
Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 1977;3(2):231–6.PubMed
32.
Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, et al. Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with Novel Monoclonal antibodies in archived tissues using tissue microarrays and Digital Microscopy. Appl Immunohistochem Mol Morphology. 2008;16(5):433–41.
33.
Parikka M, Nissinen L, KaIinulainen T, Bruckner-Tuderman L, Salo T, Heino J, et al. Collagen XVII promotes integrin-mediated squamous cell carcinoma transmigration—A novel role for αIIb integrin and tirofiban. Exp Cell Res. 2006;312(8):1431–8.PubMed
34.
Lothong M, Sakares W, Rojsitthisak P, Tanikawa C, Matsuda K, Yodsurang V. Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway. PLoS ONE. 2021;16(7):e0255179.PubMedPubMedCentral
35.
Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab Oncologist. 2010;15(8):819–25.PubMed
36.
Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: current role in treatment and the potential of Biosimilars. Target Oncol. 2017;12(5):599–610.PubMedPubMedCentral
37.
Shih T, Lindley C, Bevacizumab. An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–802.PubMed
38.
Chintala SK, Sawaya R, Gokaslan ZL, Rao JS. The effect of type III collagen on migration and invasion of human glioblastoma cell lines in vitro. Cancer Lett. 1996;102(1–2):57–63.PubMed
39.
Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001;61(8):3508–17.PubMed
40.
Nissen NI, Kehlet S, Boisen MK, Liljefors M, Jensen C, Johansen AZ, et al. Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Sci Rep. 2021;11(1):865.PubMedPubMedCentral
41.
Moilanen JM, Löffek S, Kokkonen N, Salo S, Väyrynen JP, Hurskainen T, et al. Significant role of collagen XVII and integrin β4 in Migration and Invasion of the less aggressive squamous cell carcinoma cells. Sci Rep. 2017;7(1):45057.PubMedPubMedCentral
42.
Liu CC, Lin SP, Hsu HS, Yang SH, Lin CH, Yang MH, et al. Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nat Commun. 2016;7(1):11798.PubMedPubMedCentral
43.
Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M, et al. Cell–matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022;608(7924):784–94.PubMed
44.
Schmidt E, Zillikens D. Pemphigoid diseases. The Lancet. 2013;381(9863):320–32.
45.
Nishie W. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci. 2014;73(3):179–86.PubMed
46.
Hasan Ali O, Bomze D, Ring SS, Berner F, Fässler M, Diem S, et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol. 2020;82(4):854–61.PubMed
47.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537–42.PubMedPubMedCentral
Metadata
Title
Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer
Authors
Marina Crespo-Bravo
Jeppe Thorlacius-Ussing
Neel I. Nissen
Rasmus S. Pedersen
Mogens K. Boisen
Maria Liljefors
Astrid Z. Johansen
Julia S. Johansen
Morten A. Karsdal
Nicholas Willumsen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11470-5

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Research

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias

Research

Clinical features and prognosis of cardiac metastatic tumors

Research

E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis

Study Protocol

Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

Research

Feasibility of three times weekly symptom screening in pediatric cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits